Supplemental Drug Approvals Without Clinical Trials Under Congressional Consideration
This article was originally published in The Pink Sheet Daily
Executive Summary
House Energy and Commerce Committee seeks ideas for restructuring FDA to accelerate approvals and maintain U.S. health innovation dominance in the 21st century.